Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Controlled-release paroxetine recaptures 41% of pre-seizure new prescription share, but the sales interruption still slows growth of GSK’s U.S. pharma business during the second quarter.
You may also be interested in...
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch
Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.
Takeda’s Actoplus Met For Type 2 Diabetes Will Launch In October
FDA approves the single-pill combination of Takeda’s Actos (pioglitazone) and metformin.